Kerem Can Alp's LinkedIn Strategy — Director…

Spain just made drug prices a state secret. MFN killed pricing transparency on both sides of the Atlantic. Spain's Health Commission voted 33–1 to legally prohibit disclosure of the prices it pays fo…

LinkedIn post image: Spain just made drug prices a state secret. MFN killed pricing transparency on both sides of the Atlantic.

67134

Pharmaceutical Pricing Policy16 days ago

View on LinkedIn

The US just opened a trade investigation into Germany’s drug pricing. The same mechanism used against China. This is not the opening move. MFN, investment withdrawal, and now a formal trade investiga…

LinkedIn post image: The US just opened a trade investigation into Germany’s drug pricing.

3285

Pharmaceutical Policy & Trade23 days ago

View on LinkedIn

Everyone says AI will reinvent the pharma value chain. So why is 88% of the spending concentrated in R&D? The use cases of AI are everywhere: diagnosis, supply chain, clinical ops, commercialization.…

LinkedIn post image: Everyone says AI will reinvent the pharma value chain. So why is 88% of the spending concentrated in R&D?

24121

AI in Pharmaceuticals30 days ago

View on LinkedIn

Pharma sells drugs to cure or manage diseases. But a growing number of people want to optimize their health and longevity. Not fix what is broken. 𝗧𝗵𝗶𝘀 𝗱𝗲𝗺𝗮𝗻𝗱 𝗵𝗮𝘀 𝘂𝗻𝗹𝗼𝗰𝗸𝗲𝗱 𝗮 𝗺�…

LinkedIn post image: Pharma sells drugs to cure or manage diseases. But a growing number of people want to optimize their health and longevit

2581

Healthcare & Biotech11 days ago

View on LinkedIn

While Europe complains that the US extracts its best science, Ipsen's acquisition of Kartos Therapeutics, Inc. proves that a sophisticated global division of labor is at play. In H1 2026, European mi…

LinkedIn post image: While Europe complains that the US extracts its best science, Ipsen's acquisition of Kartos Therapeutics, Inc. proves th

1811

Pharmaceutical M&A13 days ago

View on LinkedIn

Two sovereigns. Two power moves. To kill the NewCo model in US-Chinese biotech deals. First, US lawmakers targeted the increasing wave of Chinese licensing deals. BIOSECURE already restricted federa…

LinkedIn post image: Two sovereigns. Two power moves. To kill the NewCo model in US-Chinese biotech deals.

1280

Biotech Regulation19 days ago

View on LinkedIn

Topics & Content Focus

Primary Topics

Transatlantic Biopharma GeopoliticsGlobal Drug Pricing Opacity & MFN PolicyMarket Structure & Regulatory ArbitragePharma M&A and Division of Labor

Secondary Themes

Wellness & Longevity Gray MarketsEuropean Mid-cap Growth PlaybooksFDA Compounding Regulatory FrameworksTrade Tariffs and Clinical Investment Signals

Industry Focus

Global Biopharma StrategyHealth Economics & Market AccessPharmaceutical Policy & Regulation

Content Categories

Macro-Economic AnalysisRegulatory IntelligenceCorporate Strategy DeconstructionMarket Trend Forecasting

Structure & Quality

350

Avg Length (Words)

HIGH

Depth Level

ADVANCED

Expertise Level

0.95/10

Uniqueness Score

Common Hooks

The 'Contrarian Market Observation' (e.g., Spain making prices a secret)The 'Structural Dichotomy' (e.g., Pharma vs. Wellness demand)The 'Geopolitical Harbinger' quote

Common Endings

The 'Open Question' for industry leadersThe 'Wait-and-See' strategic warningSource attribution with a specific date/publication

Value Delivery Methods

Connecting disparate regulatory events to market capital flowsExplaining the 'why' behind corporate M&A movementsSynthesizing news into strategic playbooks

Formatting Style

Heavy use of bolding for emphasis (Macro-points)Bulleted lists for tactical evidenceShort, punchy paragraphs for readability

Writing Style Patterns

Content Strategy

Hook: The 'Contrarian Market Observation' (e.g., Spain making pricTone: formalCTA: Soft intellectual invitation

Writing style breakdown

The US just signaled the end of the 'open-source' era in drug development.

𝗧𝗵𝗶𝘀 𝗶𝘀𝗻'𝘁 𝗮 𝘁𝗲𝗺𝗽𝗼𝗿𝗮𝗿𝘆 𝘁𝗿𝗮𝗱𝗲 𝘀𝗾𝘂𝗮𝗯𝗯𝗹𝗲. It is a fundamental re-wiring of how biological data moves across borders.

Last night, the Department of Commerce issued a restricted entity list targeting three of the largest genomic data providers in Asia. The justification: national security risks associated with large-scale DNA sequencing.

𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗿𝗲𝘁𝗿𝗲𝗮𝘁𝗶𝗻𝗴.

Two mid-cap biotech IPOs were pulled this morning citing 'regulatory uncertainty.'

Venture debt providers are adding 'geopolitical exit' clauses to new term sheets.

Cross-border R&D collaborations are being audited for data-sovereignty compliance.

The market is realizing that science is no longer a global commons. It is a strategic asset.

𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗡𝗲𝘄𝗖𝗼 𝗺𝗼𝗱𝗲𝗹

The era of 'Discovery in Shanghai, Commercialization in Boston' is hitting a hard ceiling. If the underlying data cannot be exported for FDA review without a security clearance, the arbitrage disappears.

We are moving toward a 'Bifurcated Pipeline' reality.

Kerem Can Alp

Warm Analysis

Performance Overview

Top Posts by Engagement

Posting Patterns & Frequency

Best Performing Days

Best Performing Times To Post